What brand-name Mounjaro costs cash-pay in 2026 — retail, GoodRx, and why patients seeking tirzepatide for weight often look at Zepbound self-pay or compounded instead.
Mounjaro is FDA-approved for type 2 diabetes (often used off-label for weight). Unlike Zepbound, Lilly does not offer a dedicated self-pay vial program for Mounjaro, so cash-pay relies on retail pricing and discount cards.
| Option | Type | From / month | FDA status |
|---|---|---|---|
| Retail list price | Brand | $1,069–$1,080/mo | FDA-approved (T2D) |
| With GoodRx / discount card | Brand | $900–$1,060/mo | FDA-approved (T2D) |
| Commercial insurance + savings card | Brand | as low as $25/mo | FDA-approved (T2D) |
| Zepbound self-pay (same molecule, weight) | Brand | $299–$449/mo | FDA-approved (weight) |
| Compounded tirzepatide (for comparison) | Compounded | $186/mo (NexLife)* | Not FDA-approved |
Mounjaro and Zepbound share the same active ingredient (tirzepatide). For weight management, Zepbound's self-pay program is usually the cheaper brand route. See Mounjaro vs compounded cost.
About $1,069–$1,080/month at retail, or roughly $900–$1,060 with a GoodRx or similar discount card. Mounjaro is FDA-approved for type 2 diabetes. See NexLife pricing
For weight management, Zepbound's LillyDirect self-pay ($299–$449/mo) is usually cheaper than cash-pay Mounjaro. Both contain tirzepatide.
No. Compounded tirzepatide is not FDA-approved. Only brand-name Mounjaro (type 2 diabetes) and Zepbound (chronic weight management), made by Eli Lilly, are FDA-approved. Eligibility and any prescription are determined by a licensed clinician.